Antibody-Mediated Targeting of Alpha PDGF Receptor to Inhibit the Progression of Skeletal Micro-Metastases
Abstract
The dissemination of prostate cancer to the skeleton is the main cause of death from this tumor. Despite the effective palliative management of patients with advanced disease, curative measures are still lacking and metastatic prostate cancer is still an unmet medical need. The overarching goals of this study were to: 1) conclusively establish the role of PDGFRa; in conferring bone metastatic potential to prostate cancer cells; 2) provide pre-clinical evidence that a fully human, monoclonal antibody against this receptor impairs metastatic progression in the skeleton of animal models; 3) identify specific genes and their encoded protein products underpinning the bone-metastatic behavior of prostate cancer cells. During these three years of funding we have fully addressed all goals of our study, published several papers in high profile journals, contributed to the pre-clinical phase of an antibody currently completing phase-II clinical trails and identified a three-gene set that define the bone-metastatic behavior of human prostate cancer cells in animal models and ex-vivo human samples.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA570817
Entities
People
- Alessandro Fatatis
Organizations
- Drexel University College of Medicine